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Abstract
Background: Stroke is common in patients with end-stage renal disease (ESRD) treated with hemodialysis (HD) and 
associated with high mortality rate. In the general population, atrial fibrillation (AF) is a major risk factor for stroke and 
therapeutic anticoagulation is associated with risk reduction, whereas in ESRD the relationship is less clear.
Objective: The purpose of this study is to demonstrate the influence of AF on stroke rates and probability in those on HD 
following competing risk analyses.
Design: A national record linkage cohort study.
Setting: All renal and stroke units in Scotland, UK.
Patients: All patients with ESRD receiving HD within Scotland from 2005 to 2013 (follow-up to 2015).
Measurements: Demographic, clinical, and laboratory data were linked between the Scottish Renal Registry, Scottish 
Stroke Care Audit, and hospital discharge data. Stroke was defined as a fatal or nonfatal event and mortality derived from 
national records.
Methods: Associations for stroke were determined using competing risk models: the cause-specific hazards model and the 
Fine and Gray subdistribution hazards model accounting for the competing risk of death in models of all stroke, ischemic 
stroke, and first-ever stroke.
Results: Of 5502 patients treated with HD with 12 348.6-year follow-up, 363 (6.6%) experienced stroke. The stroke incidence 
rate was 26.7 per 1000 patient-years. Multivariable regression on the cause-specific hazard for stroke demonstrated age, 
hazard ratio (HR) (95% confidence interval [CI]) = 1.04 (1.03-1.05); AF, HR (95% CI) = 1.88 (1.25-2.83); prior stroke, HR 
(95% CI) = 2.29 (1.48-3.54), and diabetes, HR (95% CI) = 1.92 (1.45-2.53); serum phosphate, HR (95% CI) = 2.15 (1.56-
2.99); lower body weight, HR (95% CI) = 0.99 (0.98-1.00); lower hemoglobin, HR (95% CI) = 0.88 (0.77-0.99); and systolic 
blood pressure (BP), HR (95% CI) = 1.01 (1.00-1.02), to be associated with an increased stroke rate. In contrast, the 
subdistribution HRs obtained following Fine and Gray regression demonstrated that AF, weight, and hemoglobin were not 
associated with stroke risk. In both models, AF was significantly associated with nonstroke death.
Limitations: Our analyses derive from retrospective data sets and thus can only describe association not causation. Data 
on anticoagulant use are not available.
Conclusions: The incidence of stroke in HD patients is high. The competing risk of “prestroke” mortality affects the 
relationship between AF and risk of future stroke. Trial designs for interventions to reduce stroke risk in HD patients, such 
as anticoagulation for AF, should take account of competing risks affecting associations between risk factors and outcomes.
Abrégé 
Contexte: Les accidents vasculaires cérébraux (AVC) sont fréquents chez les patients atteints d’insuffisance rénale terminale 
(IRT) traités en hémodialyse (HD), et sont associés à des taux de mortalité élevés. Dans la population générale, la fibrillation 
auriculaire (FA) est un important facteur de risque de subir un AVC. L’administration d’anticoagulants est associée à une 
réduction du risque, mais cette relation demeure incertaine en contexte d’IRT.
Objectif: L’étude vise à démontrer l’influence de la FA sur la probabilité et les taux d’AVC chez les patients hémodialysés 
atteints de FA, à la suite d’analyses des risques concurrents.
Type d’étude: Une étude de cohorte par jumelage des registres nationaux.
Cadre: Toutes les unités de néphrologie et de soins spécialisés en AVC de l’Écosse (Royaume-Uni).
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Sujets: Tous les patients atteints d’IRT et traités par hémodialyse entre 2005 et 2013 en Écosse. Les patients ont été suivis 
jusqu’en 2015.
Mesures: Les données démographiques, cliniques et de laboratoire ont été jumelées aux données du Scottish Renal Registry, 
du Scottish Stroke Care Audit et aux notes inscrites dans les dossiers médicaux à la sortie de l’hôpital. Les AVC ont été classés 
comme événement fatal ou non fatal, et la mortalité a été dérivée des registres nationaux.
Méthodologie: Les associations de l’AVC ont été établies à l’aide de modèles de risques concurrents, soit un modèle de 
risque lié à la cause et l’approche de Fine et Gray, tenant compte du risque concurrent de mortalité dans les modèles incluant 
tous les types d’AVC, les AVC ischémiques et les premiers AVC.
Résultats: Des 5 502 patients hémodialysés, suivis sur un total de 12 348,6 ans, 363 (6,6 %) ont subi un AVC. Le taux 
d’incidence d’un AVC était de 26,7 pour 1000 années-patient. La régression multivariée sur le risque lié à la cause pour les 
AVC a démontré que l’âge (RR: 1,04 [IC 95 %] [1,03-1,05]), la FA (RR: 1,88 [1,25-2,83]), les antécédents d’AVC (RR 2,29 
[1,48-3,54]), le diabète (RR: 1,92 [1,45-2,53]), le taux de phosphate sérique (RR: 2,15 [1,56-2,99]), un faible poids corporel 
(RR: 0,99 [0,98-1,00]), un faible taux d’hémoglobine (RR: 0,88 [0,77-0,99]) et la pression systolique (RR: 1,01 [1,00-1,02]) 
étaient associés à un plus grand risque de subir un AVC. En revanche, les rapports de risque de sous-distribution obtenus par 
l’approche Fine et Gray ont démontré que la FA, le poids et le taux d’hémoglobine n’étaient pas associés à un risque d’AVC. 
Les deux modèles ont associé la FA à la mortalité non liée à un AVC de façon significative.
Limites: Nos analyses dérivent d’ensembles de données rétrospectives, et par conséquent, ne peuvent que décrire une 
association et non la causalité. Les informations sur l’anticoagulant prescrit n’étaient pas disponibles.
Conclusion: L’incidence des AVC chez les patients hémodialysés est élevée. Le risque concurrent de mortalité « pré-AVC » 
affecte le lien entre la FA et le risque de subir un AVC dans le futur. La conception d’essais cliniques sur les interventions 
visant à réduire les risques d’AVC chez les patients hémodialysés, notamment le traitement de la FA par les anticoagulants, 
devrait tenir compte des risques concurrents qui affectent les associations entre les facteurs de risques et les résultats.
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What was known before
The incidence of, and mortality following, stroke in patients 
on hemodialysis (HD) for end-stage renal disease (ESRD) is 
higher than in the general population. In the general popula-
tion, atrial fibrillation (AF) is associated with a 5-fold 
increase in stroke risk, a risk factor mitigated by use of anti-
coagulation. The influence of this key modifiable risk factor 
and thus the benefits from treatment are less clear in ESRD.
What this adds
This study provides a descriptive insight into the use of 
competing risk models in renal epidemiology for stroke 
after adjusting for the competing risk of death. We demon-
strate that the presence of AF is significantly associated with 
an increase in stroke rates in surviving HD recipients, 
whereas we did not detect a significant association between 
AF and stroke probability in competing risk analyses. We 
propose that the high mortality rate in HD and its associa-
tion with AF may explain the apparent lack of association of 
AF with stroke.
Introduction
The assumption that risk factors for disease in the general 
population will also predict outcome in those with end-
stage renal disease (ESRD) can be false and could lead to 
ineffective and potentially harmful treatment. For example, 
there is an established association between rising blood 
pressure (BP)1 or serum cholesterol2 and survival in the 
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general population, but “reverse epidemiology” has been 
observed in those on maintenance dialysis.3 In the absence 
of specific trials in people with ESRD, this makes estab-
lishing the best preventive care in ESRD problematic. For 
example, the absence of benefit from statin use in hyper-
cholesterolemia in people with ESRD was only appreciated 
following 3 randomized control trials in maintenance dialy-
sis patients4-6 and a meta-analysis of low-density lipopro-
tein (LDL) cholesterol–lowering therapy across a range of 
renal functions.7 Therefore, until well-designed trials 
advance our knowledge, we must make the best use of 
available observational data, to assess both efficacy and 
safety of treatments.
Stroke is common in the ESRD population and the inci-
dence is up to 10-fold greater than in the general popula-
tion.8 It is associated with a high mortality rate,9 physical 
frailty,10 cognitive dysfunction,11 and dialysis withdrawal.12 
Understanding the risk factors for stroke in ESRD is needed 
to optimize prevention. Atrial fibrillation (AF)13 is an 
important risk factor for stroke14 and risk is mitigated by 
use of anticoagulant drugs.14 However, the bleeding risk 
associated with anticoagulation is much higher in the ESRD 
population than that observed in patients without ESRD15 
and the less frequently acknowledged complications of 
warfarin are of greater significance in patients with ESRD, 
specifically accelerated vascular calcification,16 and calci-
phylaxis.17 Reports on the effects of AF are inconsistent - 
potentially because despite the increasing number of 
publications examining the factors associated with 
stroke,18-33 most fail to address an important issue of sur-
vival analysis—the concept of a competing risk. Briefly, a 
competing risk is an event that occurs during follow-up 
which forever prevents the event of interest occurring. For 
instance, in the situation of time-to-stroke analyses, death 
would act as a competing risk, forever preventing future 
stroke. Simply censoring death could lead to misinterpreta-
tion of an effect. Such risk must be acknowledged in the 
statistical models chosen.
We performed a record linkage analysis of national data 
in Scotland to examine stroke in ESRD in those receiving 
hemodialysis (HD), with focus on the following: stroke 
incidence rate, mortality following stroke, and factors 
associated with stroke occurrence. We hypothesized that 
stroke incidence rate and mortality following stroke would 
be high and that analyzing our data adjusting for the com-
peting risk of death would demonstrate the differential 
impact of risk factors on the rates and probability of stroke 
and death.
Methods
Using a National Health Service Scotland Safe Haven work-
space, we linked the Scottish Renal Registry, Scottish Stroke 
Care Audit (SSCA), Scottish Morbidity Records 01, and 
National Records Scotland Death Records over the period of 
January 1, 2005 to December 31, 2013. This created a data 
set which allowed determination of the following: (1) stroke 
incidence rates in HD, (2) factors associated with stroke in 
HD using a competing risk approach, and (3) case fatality 
following stroke.
Data sets
The Scottish Renal Registry (SRR) is a nationwide data set, 
contributed to by all 9 adult renal units. Data are collected on 
multiple variables including baseline demographics, primary 
renal diagnoses, and annual census lab and clinical vari-
ables.34 All patients receiving renal replacement therapy 
(RRT) for ESRD are included in the renal registry. Detailed 
data on cause and date of death are captured by the SRR 
allowing the inclusion of stroke cases diagnosed at, but not 
before, death.
The SSCA35 was established in 2002 to monitor the per-
formance of stroke care against guideline-based clinical 
standards throughout Scotland. Data are collected on patient 
demographics, stroke subtype, and outcomes. This data set 
had provided a complete coverage of all hospitals managing 
acute stroke since 2005.
The Scottish Morbidity Records 01 (SMR01) collects 
data on all nonobstetric, nonpsychiatric hospital discharges 
since 1968.36 Since 1989, SMR01 has been used to plan 
financial management of hospitals to ensure a high comple-
tion rate. Internal audit of these data supports overall 89% 
accuracy for Main Condition diagnosis.37
The National Records of Scotland is a nonministerial 
department of the Scottish Government, established in 2011 
following the merger of the General Register Office for 
Scotland and the National Archives of Scotland. They are 
responsible for registration of life events including deaths. 
Stroke as a cause of death was identified using enhanced 
mortality data available within the SRR’s Scottish Mortality 
Audit in Renal Replacement Therapy (SMARRT). 
However, prescription data are not available and therefore 
the potential influence of anticoagulation use on cause of 
death is not reported.
Definitions
HD Recipients
All patients commencing RRT for ESRD in Scotland are 
recorded within the SRR. End-stage renal disease is a diag-
nosis determined by the clinician initiating RRT. We 
included only adults (those ≥16 years at study inception) 
who were receiving HD. The study inception date was 
January 1, 2005 in those receiving HD at the start of the 
study period or the date of commencing HD as the first 
modality of RRT for ESRD occurring thereafter. The end 
date was recorded as the date of stroke, change in RRT 
modality, death, or end of the study.
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Stroke
All nonfatal and fatal strokes were included in our analyses. 
From the SSCA, we extracted the date and subtype of the first 
stroke during the study period. To ensure complete capture of 
stroke, SMR01 was interrogated for the presence and dates of 
International Statistical Classification of Diseases and Related 
Health Problems, Tenth Revision (ICD-10) codes pertaining 
to stroke episodes (I60, I61, I62.9, I63, and I64) excluding 
subdural and extradural hemorrhages and transient ischemic 
attack (TIA). Using SMARRT data within the SRR, all cases 
where “Cerebrovascular accident, ERA-EDTA code 22” was 
listed as the primary cause of death were extracted.
Baseline Characteristics
The SMR01 was interrogated from 1981 until December 
31, 2013 for the presence of ICD-10 codes relating to atrial 
fibrillation/flutter (I48), ischemic heart disease (I21, 24, 
24.8, I24.9, I25, I25.1, I25.2, I25.5, and I25.8), diabetes 
mellitus (E10 and E11), hypercholesterolemia (E78), obe-
sity (E66), smoking (F17), and hypertension (I10 and I15). 
To prevent the overlap of diagnoses, ICD codes for prior 
stroke (I60, I61, I62.9, I63, and I64) were pulled from 
1981 until the date of first stroke in those who experience 
stroke, or until December 31, 2013 in those who do not.
The Scottish Government provides online calculators 
allowing use of patient postcode to generate an urban-rural 
classification (http://www.isdscotland.org/Products-and-
Services /GPD-Suppor t /Geography/Urban-Rura l -
Classification/) and divisions of socioeconomic deprivation, 
the Scottish Index of Multiple Deprivation (SIMD; http://
www.gov.scot/Topics/Statistics/SIMD). Using patient post-
code at commencing RRT in those on RRT or postcode at 
stroke for the general population, deprivation quintiles were 
calculated and categorized into the most deprived (quintiles 
1 and 2) or least deprived (quintiles 3-5). Rurality classifica-
tion is based on population size and accessibility to an urban 
area. The 6-fold classification was used and subdivided into 
urban (population > 3000) and rural (population < 3000).
Clinical and Lab Values
The annual census collects data on BP, weight, use of eryth-
ropoietin-stimulating agents, and blood results, namely, 
blood hemoglobin, serum albumin, phosphate, adjusted cal-
cium, and urea reduction ratio. Data were collected and have 
been provided as a median (interquartile range [IQR]) of all 
results over the entire study period or until date of stroke, 
whichever comes first.
Statistical Analyses
Stroke incidence rates were calculated using events as the 
numerator and follow-up time in years as the denominator 
and expressed as per 1000/patient-years. Data are presented 
as median (IQR) for continuous data or total number (%) for 
categorical data. Demographics are compared using Mann-
Whitney U or chi-square test as appropriate. Using predeter-
mined clinical factors relating to stroke or cardiovascular 
outcome (age, sex, past medical history of AF, stroke, diabe-
tes and ischemic heart disease, predialysis systolic BP, predi-
alysis weight, blood hemoglobin, and serum phosphate), we 
performed 2 competing risk analyses. Firstly, to analyze the 
effect of covariates on the rate at which events occur, we 
performed multivariable cause-specific Cox proportional 
hazards analyses to calculate the cause-specific hazard 
(CSH) ratios for stroke and nonstroke death, presented as 
CSH ratios with 95% confidence intervals (CIs). We ensured 
that there was no significant multicollinearity between vari-
ables by calculating the variance inflation factor, using a cut-
off of 5. Secondly, to determine which variables affect the 
probability of each event occurring over time (incidence), we 
used the Fine and Gray regression model, calculating the 
subdistribution hazard ratio (SHR) for the occurrence of 
stroke and also prestroke death. Analyses were repeated to 
assess 3 distinct groups: (1) all stroke cases, (2) ischemic 
stroke only by omitting all cases of hemorrhagic stroke, and 
(3) first-ever stroke by removing all cases with a prior his-
tory of stroke. Finally, we used both the Kaplan-Meier (KM) 
estimator and the cumulative incidence competing risk 
(CICR) method to calculate the cumulative incidence of 
stroke and prestroke death based on the presence or absence 
of AF. We did not perform imputation for missing data as 
missing data were not missing at random. Data linkage was 
performed using SAS v9.4 (SAS Institute Inc, Cary, North 
Carolina), and analyses, including competing risk analyses, 
were performed using Stata 14.1 (StataCorp, College Station, 
Texas). We used the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) cohort 
checklist when writing our report.38
Ethical Approval
The data sets used in this article work within the “NHS Code 
of Practice on Protecting Patient Confidentiality” which 
incorporates the requirements of statute and common law 
including the Data Protection Act, the Human Rights Act, 
and the Adults with Incapacity (Scotland) Act. Access and 
use of the data for the purpose of this study were approved 
following a National Services for Scotland (NSS) propor-
tionate governance review by the Privacy Advisory 
Committee of ISD, NHS Scotland Reference 55/14.
Results
Characteristics of the Study Population
A total of 5502 adult patients were receiving or commenced 
HD for ESRD between January 1, 2005 and December 31, 
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2013 in Scotland. The median age (IQR) at commencing 
RRT was 65.1 (23.3) years, and 2271 (41.3%) were female. 
Median duration of follow-up was 665 (1098) days. Baseline 
characteristics of the cohort are shown in Table 1 with demo-
graphics of subjects with and without AF (as a variable of 
interest) in Table 2.
There were 363 strokes during the follow-up period 
accounting for 6.6% of all patients; 45 (12.4%) were hem-
orrhagic, and the remainder were ischemic or unspecified 
(including those listed as primary cause of death). 
Cumulative follow-up was 12 348.6 years. Unadjusted 
stroke incidence rate for all ESRD patients is 26.7 strokes 
per 1000 patient-years. The incidence rate of stroke in the 
incident population (≤90 days of RRT) was 36.4 per 1000 
patient-years.
Demographics demonstrate that those who experience 
stroke were more likely to be older and have diabetic 
nephropathy, a past medical history of AF, prior stroke, dia-
betes, and hypercholesterolemia. Clinical variables revealed 
higher median systolic BP, lower body weight, higher median 
serum phosphate, and lower median serum calcium in those 
who experience stroke.
Table 1. Baseline Demographics of HD Patients—No Stroke Versus All Stroke.
No stroke Stroke All P value
n 5139 363 5502  
Median age (IQR), years 64.8 [24.0] 69.9 [15.4] 65.1 [23.3] <.0001
Female (%) 2105 [41.0] 166 [45.7] 2271 [41.3] .08
Primary renal diagnosis (%)
 Glomerulonephritis 748 [14.6] 44 [12.1] 792 [14.4] .22
 Interstitial disease 1093 [21.3] 64 [17.6] 1157 [21.0] .11
 Multisystem 1262 [24.6] 94 [25.9] 1356 [24.7] .57
 Diabetes 1085 [21.1] 98 [27.0] 1183 [21.5] .01
 Other 941 [18.3] 63 [17.4] 1004 [18.3] .73
 Missing 10 [0.2] 10 [0.2]  
Urban rurality status (%)
 Urban 773 [15.0] 54 [14.9] 827 [15.0]  
 Rural 4366 [85.0] 309 [85.1] 4675 [85.0] 1.00
Deprivation status (%)
 Least (SIMD quintiles 3-5) 3722 [72.4] 259 [71.4] 3981 [72.4]  
 Most (SIMD quintiles 1 and 2) 1417 [27.6] 104 [28.7] 1521 [27.6] .67
Past medical history (%)  
 Atrial fibrillation 384 [7.5] 45 [12.4] 429 [7.8] <.01
 Ischemic heart disease 1774 [34.5] 138 [38.0] 1912 [34.8] .19
 Stroke 197 [3.8] 36 [9.9] 233 [4.2] <.0001
 Diabetes 1772 [34.5] 148 [40.8] 1920 [34.9] .02
 Hypercholesterolemia 679 [13.2] 66 [18.2] 745 [13.5] .01
 Obesity 352 [6.9] 25 [6.9] 377 [6.9] 1.00
 Smoking 317 [6.2] 14 [3.9] 331 [6.0] .09
 Hypertension 3649 [71.0] 271 [74.7] 3920 [71.3] .17
Clinical variables, median (IQR)
 SBP, mm Hg 138 [29.0] 142 [30.0] 138.5 [29.0] <.01
 DBP, mm Hg 71 [18.5] 69 [20.0] 71 [18.5] .25
 Weight, kg 72.8 [23.5] 70.25 [25.6] 72.6 [23.6] <.01
 Use of ESA 3791 [73.8] 251 [69.2] 4042 [73.5] .056
Laboratory variables, median (IQR)
 Hemoglobin, g/dL 11.4 [1.8] 11.3 [1.6] 11.35 [1.8] .29
 Serum albumin, g/L 37 [7.0] 36.5 [7.0] 37 [7.0] .53
 Serum phosphate, mmol/L 1.46 [0.56] 1.56 [0.58] 1.47 [0.56] <.01
 Serum adjusted calcium, mmol/L 2.36 [0.19] 2.33 [0.20] 2.36 [0.20] <.01
 Urea reduction ratio 71.5 [8.5] 71 [10] 71.5 [8.5] .99
Death at follow-up 3152 [61.3] 328 [90.4] 3480 [63.3] <.0001
Note. IQR = interquartile range; SIMD = Scottish Index of Multiple Deprivation; SBP = systolic blood pressure; DBP = diastolic blood pressure;  
ESA = erythropoietin-stimulating agent; HD = hemodialysis.
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Survival Analyses: Cause-Specific Hazards and 
Subdistribution Hazards Model Regressions
The rate of event occurrence was assessed by multivariable 
regression on the CSH for stroke. This demonstrated signifi-
cance for conventional stroke risk factors, namely, age (haz-
ard ratio [HR] [95% CI] = 1.04 [1.03-1.05]), presence of AF 
(HR [95% CI] = 1.88 [1.25-2.83]), prior stroke (HR [95% 
CI] = 2.29 [1.48-3.54]), and diabetes (HR [95% CI] = 1.92 
[1.45-2.53]). Higher median serum phosphate (HR [95% CI] 
= 2.15 [1.56-2.99]) was associated with a greater stroke rate, 
as was lower body weight (HR [95% CI] = 0.99 [0.98-
1.00]), lower median hemoglobin (HR [95% CI] = 0.88 
[0.77-0.99]), and higher predialysis systolic BP (HR [95% 
CI] = 1.01 [1.00-1.02]). The Fine and Gray subdistribution 
hazards model was used to determine factors which influ-
ence the probability of stroke occurrence over time. This 
demonstrated an increase in stroke risk from increasing age, 
prior stroke, diabetes, serum phosphate, and systolic BP. 
There was no significant effect of AF, weight, or hemoglobin 
on stroke risk. In both competing risk models, AF was sig-
nificantly associated with mortality (see Table 3).
Table 2. Baseline Demographics of HD Patients Split by the Presence of Atrial Fibrillation.
No AF AF All P value
n 5073 429 5502  
Median age (IQR), years 64.6 [23.9] 70.9 [15.8] 65.1 [23.3] <.0001
Female (%) 2114 [41.67] 157 [36.6] 2271 [41.3] .04
Primary renal diagnosis (%)
 Glomerulonephritis 729 [14.4] 63 [14.7] 792 [14.4] .83
 Interstitial disease 1081 [21.3] 76 [17.7] 1157 [21.0] .08
 Multisystem 1245 [24.5] 111 [25.9] 1356 [24.7] .56
 Diabetes 1104 [21.8] 79 [18.4] 1183 [21.5] .11
 Other 907 [17.9] 97 [22.6] 1004 [18.3] .02
 Missing 7 [0.1] 3 [0.7] 10 [0.2]  
Urban rurality status (%)
 Urban 770 [15.2] 57 [13.3] 827 [15.0]  
 Rural 4303 [84.8] 372 [86.7] 4675 [85.0] .32
Deprivation status (%)
 Least (SIMD quintiles 3-5) 3672 [72.4] 309 [72.0] 3981 [72.4]  
 Most (SIMD quintiles 1 and 2) 1401 [27.6] 120 [28.0] 1521 [27.6] .87
Past medical history (%)
 AF 0 429 [100] 429 [7.8] <.0001
 Ischemic heart disease 1678 [33.1] 234 [54.6] 1912 [34.8] <.0001
 Stroke 193 [3.8] 40 [9.3] 233 [4.2] <.0001
 Diabetes 1773 [35.0] 147 [34.3] 1920 [34.9] .79
 Hypercholesterolemia 679 [13.4] 66 [15.4] 745 [13.5] .27
 Obesity 339 [6.7] 38 [8.9] 377 [6.9] .07
 Smoking 314 [6.2] 17 [4.0] 331 [6.0] .07
 Hypertension 3575 [70.5] 345 [80.4] 3920 [71.3] <.0001
Clinical variables, median (IQR)
 SBP, mm Hg 139.0 [29.0] 132.3 [31.8] 138.5 [29.0] <.0001
 DBP, mm Hg 71.0 [19.0] 68 [18.3] 71 [18.5] <.01
 Weight, kg 72.6 [23.8] 72.8 [22.0] 72.6 [23.6] .92
 Use of ESA 3765 [74.2] 277 [64.6] 4042 [73.5] <.0001
Laboratory variables, median (IQR)
 Hemoglobin, g/dL 11.4 [1.8] 11.5 [1.8] 11.4 [1.8] .15
 Serum albumin, g/L 37.0 [7.0] 36.5 [7.0] 37.0 [7.0] .05
 Serum phosphate, mmol/L 1.47 [0.56] 1.50 [0.54] 1.47 [0.56] .02
 Serum adjusted calcium, mmol/L 2.35 [0.19] 2.36 [0.21] 2.36 [0.20] .71
 Urea reduction ratio 71.5 [9.0] 70 [9] 71.5 [8.5] .13
Stroke cases 318 [6.3] 45 [10.5] 363 [6.6] <.01
Death at follow-up 3087 [60.9] 393 [91.6] 3480 [63.3] <.0001
Note. Mann-Whitney U or chi-square test is applied, when comparing HD with transplant and PD with transplant. AF = atrial fibrillation;  
IQR = interquartile range; SIMD = Scottish Index of Multiple Deprivation; SBP = systolic blood pressure; DBP = diastolic blood pressure;  
ESA = erythropoietin-stimulating agent; HD = hemodialysis.
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The models were repeated for those with ischemic stroke 
(Table 4) and those with first-ever stroke (Table 5). Variables 
consistently associated with stroke were age, diabetes, prior 
stroke (where applicable), and higher serum phosphate.
Both KM estimates and CICR curves show a positive influ-
ence of AF on stroke and nonstroke death. However, the over-
estimation of this risk by the KM estimate due to the presence 
of a competing risk is observed (see Figures 1 and 2).
Outcome Following Stroke
Case fatality (death within 7 days) for all stroke cases was 
22.6% (n = 82) and 328 of 363 (90.4%) died during follow-
up. Fatality was 34.7% at 28 days and 61.7% at 1 year. 
Fatality was higher in those with hemorrhagic stroke with 
respective 7-, 28-, and 365-day fatality of 33.3%, 51.1%, and 
82.2% compared with 21.1%, 32.4, and 58.8%.
Table 3. Regression Analyses Using Competing Risk Techniques for All Stroke and Prestroke Death in Hemodialysis Patients.
Cause-specific hazards model Subdistribution hazards model
 Stroke Prestroke death Stroke Prestroke death
 HR (95% CI) P value HR (95% CI) P value SHR (95% CI) P value SHR (95% CI) P value
Demographics
 Age (years) 1.04 (1.03-1.05) <.001 1.04 (1.04-1.05) <.001 1.02 (1.01-1.04) <.001 1.03 (1.03-1.04) <.001
 Female 0.96 (0.72-1.28) .80 0.72 (0.64-0.80) <.001 1.12 (0.86-1.46) .40 0.75 (0.67-0.84) <.001
Past medical history
 Atrial fibrillation 1.88 (1.25-2.83) <.01 1.60 (1.36-1.88) <.001 1.53 (1.00-2.32) .05 1.40 (1.18-1.67) <.001
 Prior stroke 2.29 (1.48-3.54) <.001 1.10 (0.87-1.38) .44 2.30 (1.49-3.54) <.001 1.03 (0.80-1.32) .83
 Diabetes 1.92 (1.45-2.53) <.001 1.63 (1.64-1.82) <.001 1.54 (1.17-2.02) <.01 1.45 (1.30-1.62) <.001
 Ischemic heart disease 0.89 (0.68-1.56) .38 0.98 (0.88-1.08) .69 0.96 (0.74-1.25) .76 1.04 (0.93-1.15) .51
Clinical variable
 Predialysis SBP 1.01 (1.00-1.02) <.01 1.00 (0.99-1.00) <.001 1.01 (1.00-1.02) <.01 0.99 (0.99-1.00) <.001
 Predialysis weight 0.99 (0.98-1.00) <.01 0.99 (0.98-0.99) <.001 0.99 (0.98-1.00) .09 0.99 (0.99-0.99) <.001
Hemoglobin 0.88 (0.77-0.99) .04 0.75 (0.71-0.78) <.001 1.00 (0.91-1.1) .93 0.76 (0.72-0.81) <.001
 Serum phosphate 2.15 (1.56-2.99) <.001 2.05 (1.80-2.34) <.001 1.54 (1.1-2.14) .01 1.52 (1.24-1.85) <.001
Note. Initially, a cause-specific Cox proportional hazards regression examines multivariable models for stroke and prestroke death. The competing risk 
model presents multivariable regression for stroke or prestroke death using the Fine and Gray model of subdistribution hazards. HR = hazard ratio;  
CI = confidence interval; SHR = subdistribution hazard ratio; SBP = systolic blood pressure.
Table 4. Regression Analyses, Using Competing Risk Techniques for Ischemic Stroke and Prestroke Death in Hemodialysis Patients.
Cause-specific hazards model Subdistribution hazards model
 Stroke Prestroke death Stroke Prestroke death
 HR (95% CI) P value HR (95% CI) P value SHR (95% CI) P value SHR (95% CI) P value
Demographics
 Age (years) 1.04 (1.03-1.05) <.001 1.04 (1.04-1.05) <.001 1.03 (1.02-1.05) <.001 1.04 (1.03-1.04) <.001
 Female 1.08 (0.80-1.45) .61 0.72 (0.64-0.80) <.001 1.26 (0.95-1.66) .11 0.72 (0.64-0.81) <.001
Past medical history
 Atrial fibrillation 1.88 (1.22-2.90) <.01 1.60 (1.36-1.88) <.001 1.52 (0.97-2.37) .07 1.38 (1.15-1.65) <.001
 Prior stroke 2.46 (1.57-3.86) <.001 1.10 (0.87-1.38) .43 2.47 (1.58-3.86) <.001 1.01 (0.78-1.30) .96
 Diabetes 2.07 (1.54-2.78) <.001 1.63 (1.46-1.82) <.001 1.65 (1.24-2.20) <.01 1.48 (1.32-1.65) <.001
 Ischemic heart disease 0.91 (0.69-1.20) .50 0.98 (0.88-1.08) .63 0.98 (0.74-1.29) .88 1.01 (0.91-1.12) .83
Clinical variable
 Predialysis SBP 1.01 (1.00-1.01) .03 1.00 (0.99-1.00) <.001 1.01 (1.00-1.01) .1 0.99 (0.99-1.00) <.001
 Predialysis weight 0.99 (0.98-1.00) .12 0.99 (0.98-0.99) <.001 0.99 (0.98-1.00) .20 0.99 (0.99-0.99) <.001
Hemoglobin 0.89 (0.78-1.02) .09 0.74 (0.71-0.78) <.001 1.02 (0.91-1.13) .78 0.77 (0.73-0.81) <.001
 Serum phosphate 2.00 (1.39-2.87) <.001 2.04 (1.79-2.33) <.001 1.45 (1.09-1.93) .01 1.81 (1.55-2.11) <.001
Note. Initially, a cause-specific Cox proportional hazards regression examines multivariable models for stroke and prestroke death. The competing risk 
model presents multivariable regression for stroke or prestroke death using the Fine and Gray model of subdistribution hazards. HR = hazard ratio;  
CI = confidence interval; SHR = subdistribution hazard ratio; SBP = systolic blood pressure.
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Table 5. Regression Analyses Using Competing Risk Techniques for First-Ever Stroke and Prestroke Death in Hemodialysis Patients.
Cause-specific hazards model Subdistribution hazards model
 Stroke Prestroke death Stroke Prestroke death
 HR (95% CI) P value HR (95% CI) P value SHR (95% CI) P value SHR (95% CI) P value
Demographics
 Age (years) 1.04 (1.03-1.05) <.001 1.04 (1.04-1.05) <.001 1.03 (1.02-1.04) <.001 1.04 (1.03-1.04) <.001
 Female 0.95 (0.71-1.27) .71 0.70 (0.63-0.79) <.001 1.13 (0.85-1.49) .41 0.74 (0.66-0.83) <.001
Past medical history
 Atrial fibrillation 1.81 (1.16-2.81) <.01 1.60 (1.35-1.89) <.001 1.47 (0.93-2.32) .10 1.41 (1.18-1.69) <.001
 Prior stroke — — — — — — — —
 Diabetes 2.06 (1.54-2.76) <.001 1.63 (1.46-1.83) <.001 1.66 (1.25-2.20) <.001 1.44 (1.28-1.62) <.001
 Ischemic heart disease 0.86 (0.65-1.14) .29 0.97 (0.88-1.08) .61 0.94 (0.71-1.25) .68 1.04 (0.93-1.15) .49
Clinical variable
 Predialysis SBP 1.01 (1.00-1.01) .02 1.00 (0.99-1.00) <.001 1.01 (1.00-1.01) .01 0.99 (0.99-1.00) <.001
 Predialysis weight 0.99 (0.98-1.00) <.01 0.99 (0.98-0.99) <.001 0.99 (0.98-1.00) .09 0.99 (0.99-0.99) <.001
Hemoglobin 0.85 (0.75-0.97) .02 0.75 (0.71-0.78) <.001 0.98 (0.88-1.09) .71 0.77 (0.73-0.81) <.001
 Serum phosphate 2.22 (1.56-3.11) <.001 2.13 (1.86-2.43) <.001 1.56 (1.11-2.19) .01 1.54 (1.25-1.89) <.001
Note. Initially, a cause-specific Cox proportional hazards regression examines multivariable models for stroke and prestroke death. The competing risk 
model presents multivariable regression for stroke or prestroke death using the Fine and Gray model of subdistribution hazards. HR = hazard ratio;  
CI = confidence interval; SHR = subdistribution hazard ratio; SBP = systolic blood pressure.
Figure 1. Effect of prior AF on stroke incidence using the KM estimator and the cumulative incidence function curve.
Note. Although both images demonstrate a significant univariable association of AF with stroke (P < .01), this comparison graphically demonstrates the 
overestimation of cumulative incidence from the KM estimator when the competing risk of prestroke death is not considered. AF = atrial fibrillation;  
KM = Kaplan-Meier.
Figure 2. Effect of prior AF on the incidence of prestroke death using the KM estimator and the cumulative incidence function curve.
Note. Both images demonstrate a significant univariable association of AF with prestroke mortality (P < .01) and demonstrate the overestimation of 
cumulative incidence from the KM estimator when the competing risk of stroke is not considered. AF = atrial fibrillation; KM = Kaplan-Meier.
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Discussion
Following the linkage of national data sets, we have gained 
further insight into the incidence, associations, and outcomes 
of stroke in a UK-based HD population. We have highlighted 
the high incidence of stroke in HD patients and a notable 
increase in stroke incidence in the first 90 days after starting 
dialysis. This highlights both the importance of this condi-
tion and also a period of greater risk for our patients. 
Furthermore, we have described the fatality following stroke, 
with alarming results—such that less than 50% are alive 1 
year later. Recognizing this underpins the critical need to 
accurately identify treatable risk factors for stroke—targets 
for preventive strategies in dialysis patients. Finally, we have 
used our data to highlight an often-ignored consideration in 
survival analysis, that is, competing risks.
Stroke Incidence and Associations
Our stroke incidence and case fatality rates are comparable 
to previously published literature,8,39-42 and the findings of 
advancing age, prior stroke, diabetes, low body weight, 
and low blood hemoglobin are recognized.43 Unique to our 
study, high serum phosphate was found to be significantly 
associated with stroke, persisting throughout all our analy-
ses. The effect of AF on the development of stroke in 
ESRD remains unclear. In this study, AF, modeling on the 
CSH, demonstrated an increase in rates of stroke and pre-
stroke death. However, our mortality rate is high—63% of 
all patients deceased at follow-up; thus, assessing the 
probability of stroke occurrence in this context requires 
complementary data from the subdistribution hazard. In 
doing so, we discovered that AF failed to demonstrate a 
significant effect on stroke risk. We explore the reasons 
behind this.
Competing Risk Analyses in Clinical Practice
As described, a competing risk is an event arising during a 
study which can interfere with the event of interest occur-
ring.44 In our study, where stroke is our event of interest, 
death is an important competing risk as it will forever pre-
vent this event of interest occurring. Bluntly, it is impossible 
to present with stroke after death.
The survival analyses by the KM estimator and Cox 
regression models are frequently used to demonstrate the 
influence of variables on outcome incidence (ie, the proba-
bility of occurrence) or hazard (ie, the rate of occurrence in 
those still at risk), respectively. Both methods are capable of 
handling data with incomplete follow-up time. They do so by 
censoring patients who cannot be followed up to their event 
of interest, for whatever reason, or at study completion. A 
key assumption of survival analyses states that censoring 
should be independent,45 that is, a random event such that 
those censored out of the study have the same future risk of 
the event of interest as those remaining in the study.
In our study, if we fail to consider death as a competing 
risk and simply censor such patients, this would leave such 
cases in the KM estimator, remaining “at risk” for the dura-
tion of the study, which is clearly impossible. In situations 
where death rates are high or follow-up prolonged, this can 
lead to significant overestimations in stroke incidence. In 
Cox regression, a competing risk will inflate the relative dif-
ferences between groups, resulting in biased HRs and misin-
terpretations of the variable effect.
No statistical test can detect the presence of a competing 
risk; thus, when considering any event of interest, the 
researcher must carefully consider if any censored outcomes 
could interfere with the likelihood of the event of interest.
Two techniques are available via common statistical 
packages: modeling on the CSH and modeling on the sub-
distribution hazard.46 The CSH is the instantaneous rate of 
the event of interest in subjects free of any event and thus 
“specific” to the event of interest, that is, only those capa-
ble of having the event of interest remain in the risk set. The 
subdistribution hazard is the instantaneous rate of the event 
of interest in those who have not had the event of interest 
and includes those who may have had the competing risk. 
Therefore, SHR is a ratio in a nonexistent population and as 
such should not be interpreted as an HR. In simple terms, a 
subdistribution hazard > 1 means that the cumulative inci-
dence of the event is higher in subjects with this variable at 
the start of the study than those without. Relating this to our 
study, the CSH for stroke describes the instantaneous rate 
of stroke in those who have not yet experienced stroke and 
are still alive, whereas the subdistribution hazard for stroke 
is the instantaneous rate of stroke in a group who have not 
yet experienced stroke and includes those who died prior to 
stroke. Presenting both methods provides the reader with 
complementary information; the CSH is better suited to 
describe the cause of disease, whereas the subdistribution 
hazard is useful in prognosis and treatment planning. 
Therefore, our data suggest that although AF associates 
with stroke in those on HD, its presence is more likely to 
predict death prior to stroke occurrence.
An important message to conclude this section is that the 
effect of a competing risk on survival analysis is greater if 
the competing risk is frequent. An absolute competing risk 
event of >10% merits serious consideration.45 Therefore, it 
is imperative that in renal epidemiology we consider death 
as a competing risk. The lack of clarity on the influence of 
AF on stroke risk is perhaps a little more understandable 
when the literature is reviewed.18-33 We found only 1 
study from this century considering death as a competing 
risk (see Table 6).
AF and Stroke in ESRD
Our findings demonstrate, as others have,18,19,22-24,27,28,32,33 
that AF is significantly associated with death. However, 
the effect of AF on stroke remains less clear. In this study, 
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the presence of AF is associated with all-cause mortality; 
however, in our subdistribution hazards model, the influ-
ence of AF on stroke incidence lacks significance, a find-
ing more obvious in ischemic or first-ever strokes. As 
discussed, the subdistribution hazard is useful for progno-
sis and treatment planning, and thus the interpretation of 
this message is important. Presently, the only licensed oral 
anticoagulation in use in the UK HD population is the vita-
min K antagonist, warfarin, although direct-acting oral 
anticoagulants are used widely in the United States.47 
Anticoagulation carries a higher risk of bleeding in ESRD 
and vitamin K antagonism is also associated with vascular 
calcification and calciphylaxis. The inherently high 
CHA2DS2-VASc score in the HD population would prompt 
anticoagulation prescription in the majority. We lack pre-
scription data in our study to adjust for prescription of anti-
coagulation and so can only speculate on what degree of 
prestroke death associated with AF may be attributable, 
directly or indirectly, to complications such as major 
bleeding. In addition, the undeniable association of AF and 
stroke in the general population highlights the current need 
for a trial of anticoagulation in HD patients, an issue high-
lighted in a recent National Kidney Foundation’s Kidney 
Disease Outcomes Quality Initiative (NKF-KDOQI) 
report.48 However, such a trial must be powered taking into 
account that the chosen intervention is likely to have a 
meaningful effect on ischemic stroke in ESRD patients 
with AF, but the observed benefit may be influenced by the 
high background mortality rate.
Limitations
We present data from large national data sets and provide 
insight into competing risk analysis and its influence on 
prior analyses of stroke risk. However, we must acknowl-
edge the following limitations. First, our data are retrospec-
tive and as such can only be used to describe association 
and not causation. Furthermore, our data use coded diagno-
ses to identify stroke; however, both sources are validated 
by stroke physicians (SSCA) or audit (SMR01) confirming 
an approximately 90% accuracy rate. We do not have access 
to prescription data to assess the effect of warfarin on AF. 
Although these data may have provided further informa-
tion, it should be noted that no nationally held data set con-
tains information on international normalised ratio, thus 
limiting its usefulness. Finally, it must be acknowledged 
that the prevalence of AF in this cohort is at the lower end 
of the range demonstrated in previous studies (5.7%-26.9%) 
and thus may underpower the detection of an association. 
This is highlighted in Tables 3 to 5 where the wide reported 
CIs for AF following competing risk adjustment prevent 
one from completely excluding AF as a risk factor for 
stroke, albeit a risk far lower than that imposed by AF in the 
general population.
Conclusions
This study has confirmed the high incidence of stroke in 
HD patients, with a disturbingly high mortality rate and 
highlighted the difficulties with assessing factors associ-
ated with stroke. We have attempted to explain the con-
cept of competing risks as perhaps one reason for the lack 
of consistent reports regarding AF and stroke risk. We rec-
ommend all researchers consider competing risk in future 
studies.
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